Articles from ArrePath
ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor’easter Ventures, and new investor AB Magnitude.
By ArrePath · Via Business Wire · June 23, 2025

ArrePath today announced that it has appointed two new members to its Scientific Advisory Board (SAB): Connor Coley, PhD, Henri Slezynger (1957) Career Development Assistant Professor in Chemical Engineering at MIT, and Paul Hergenrother, PhD, Kenneth L. Rinehart Jr. Endowed Chair in Natural Products Chemistry, and Professor of Chemistry at the University of Illinois Urbana-Champaign.
By ArrePath · Via Business Wire · November 18, 2022

ArrePath today announced the appointment of Michael Dudley, PharmD, as Chairman of the Company’s Board of Directors.
By ArrePath · Via Business Wire · March 24, 2022